The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

Baby boomers and users of weight loss drugs suffering from “facial sagging” are flocking to injectable aesthetic treatments ...